Michele Del Vecchio

12.6k total citations · 1 hit paper
169 papers, 5.1k citations indexed

About

Michele Del Vecchio is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Michele Del Vecchio has authored 169 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Oncology, 77 papers in Molecular Biology and 44 papers in Immunology. Recurrent topics in Michele Del Vecchio's work include Melanoma and MAPK Pathways (68 papers), Cancer Immunotherapy and Biomarkers (62 papers) and CAR-T cell therapy research (47 papers). Michele Del Vecchio is often cited by papers focused on Melanoma and MAPK Pathways (68 papers), Cancer Immunotherapy and Biomarkers (62 papers) and CAR-T cell therapy research (47 papers). Michele Del Vecchio collaborates with scholars based in Italy, United States and Australia. Michele Del Vecchio's co-authors include Emilio Bajetta, Andrea Anichini, Paola Queirolo, Paolo A. Ascierto, Giorgio Parmiani, Vanna Chiarion‐Sileni, Lorenza Di Guardo, Stefania Canova, Michael T. Lotze and Amy Wesa and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Michele Del Vecchio

161 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

2017 482 citations Caroline Robert, Jean‐Jacques Grob et al. profile →

Peers

Michele Del Vecchio

ONCOL

IMMUN

PRM

SURGE

William H. Sharfman United States

Ravindra Uppaluri United States

Tullia C. Bruno United States

Robert O. Dillman United States

Raanan Berger Israel

Alessandra Cesano United States

Marcus O. Butler Canada

Austin Miller United States

Kiyohiko Hatake Japan

John B. Sunwoo United States

William H. Sharfman United States

Michele Del Vecchio

4.6k ×1.3

ONCOL

1.2k ×0.7

2.0k ×1.3

IMMUN

1.3k ×1.3

PRM

550 ×1.4

SURGE

Citations per year, relative to Michele Del Vecchio Michele Del Vecchio (= 1×) peers William H. Sharfman

Countries citing papers authored by Michele Del Vecchio

Since Specialization

Citations

This map shows the geographic impact of Michele Del Vecchio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Del Vecchio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Del Vecchio more than expected).

Fields of papers citing papers by Michele Del Vecchio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Del Vecchio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Del Vecchio. The network helps show where Michele Del Vecchio may publish in the future.

Co-authorship network of co-authors of Michele Del Vecchio

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Del Vecchio. A scholar is included among the top collaborators of Michele Del Vecchio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Del Vecchio. Michele Del Vecchio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2025). 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma. Annals of Oncology. 36. S887–S888.

Dummer, Reinhard, Jean‐Jacques Grob, Caroline Robert, et al.. (2024). Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.. Journal of Clinical Oncology. 42(16_suppl). 9506–9506. 2 indexed citations

Ascierto, Paolo A., Pietro Quaglino, Francesco Spagnolo, et al.. (2024). Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA9513–LBA9513. 2 indexed citations

Luke, Jason J., Paolo A. Ascierto, Muhammad Adnan Khattak, et al.. (2023). Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.. Journal of Clinical Oncology. 41(17_suppl). LBA9505–LBA9505. 7 indexed citations

Long, Georgina V., John M. Kirkwood, Christoph Höeller, et al.. (2023). Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).. Journal of Clinical Oncology. 41(16_suppl). 9504–9504. 8 indexed citations

Wiggins, Jennifer, Hao Tang, Keyur Desai, et al.. (2023). Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.. Journal of Clinical Oncology. 41(16_suppl). 9577–9577. 3 indexed citations

Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2023). 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology. 34. S653–S654. 2 indexed citations

D’Amico, Federica, Marco Fabbrini, Luigi Mariani, et al.. (2023). Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma. International Journal of Molecular Sciences. 24(14). 11611–11611. 10 indexed citations

Vecchio, Michele Del, et al.. (2022). Flood Susceptibility Mapping Using a Deep Neural Network Model: The Case Study of Southern Italy. SHILAP Revista de lepidopterología. 36–36. 7 indexed citations

10.

Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2021). Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research. 27(17). 4737–4745. 41 indexed citations

11.

Vecchio, Michele Del, et al.. (2021). A Zero-Order Flood Damage Model for Regional-Scale Quick Assessments. Water. 13(9). 1292–1292. 3 indexed citations

12.

Aglietta, Massimo, Vanna Chiarion‐Sileni, Paolo Fava, et al.. (2021). Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Targeted Oncology. 16(6). 789–799. 5 indexed citations

13.

Cavalieri, Stefano, Sara Ronchi, Amelia Barcellini, et al.. (2021). Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiotherapy and Oncology. 164. 1–5. 14 indexed citations

14.

Indini, Alice, Lorenza Di Guardo, Carolina Cimminiello, et al.. (2019). Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. Journal of Gynecologic Oncology. 30(6). e94–e94. 33 indexed citations

15.

Ascierto, Paolo A., Pier Francesco Ferrucci, Rosalie Fisher, et al.. (2019). Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine. 25(6). 941–946. 219 indexed citations

16.

Vecchio, Michele Del. (2016). Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab. Recenti Progressi in Medicina. 107(8). 414–7. 3 indexed citations

17.

Geldres, Claudia, Barbara Savoldo, Valentina Hoyos, et al.. (2013). T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo. Clinical Cancer Research. 20(4). 962–971. 80 indexed citations

18.

Vecchio, Michele Del, Roberta Mortarini, Stefania Canova, et al.. (2010). Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clinical Cancer Research. 16(23). 5862–5872. 44 indexed citations

19.

Yvon, Eric, Michele Del Vecchio, Barbara Savoldo, et al.. (2009). Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells. Clinical Cancer Research. 15(18). 5852–5860. 113 indexed citations

20.

Pusceddu, Sara, Emilio Bajetta, Roberto Buzzoni, et al.. (2008). Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report. International Journal of Gynecological Pathology. 27(4). 596–600. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact